Amgen Shows New Patents Can Affect Prior BPCIA Litigation
On Aug. 7, 2018, Amgen and Amgen Manufacturing Limited (collectively, "Amgen") sued Apotex Inc. and Apotex Corp. (collectively, "Apotex") in a third lawsuit[1] over Apotex's pending biologics license applications, or BLAs,...To view the full article, register now.
Already a subscriber? Click here to view full article